Download presentation
Presentation is loading. Please wait.
Published byLaurel Franklin Modified over 5 years ago
1
Interaction between reboxetine and ADRA2B genotype influences post-treatment symptoms of irritability, anxiety, and dizziness. Interaction between reboxetine and ADRA2B genotype influences post-treatment symptoms of irritability, anxiety, and dizziness. A, Significant decrease in post-treatment irritability in ADRA2B deletion carriers under placebo that was absent in nondeletion carriers. B, Significant decrease in anxiety in ADRA2B deletion carriers under placebo compared with reboxetine. C, Significant increase in dizziness in ADRA2B nondeletion carriers under reboxetine compared with placebo. *p < **p < ***p < Bars indicate SEM. Ayana A. Gibbs et al. J. Neurosci. 2013;33: ©2013 by Society for Neuroscience
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.